Looking back at human anaplasmosis cases after tick bites in Alsace
Reviews past anaplasmosis cases in Alsace to describe symptoms, test results and patterns.
Key facts
- Who runs it
- University Hospital, Strasbourg, France
- Where
- France1 site in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- Epidemiological, Clinical and Biological Characteristics of Human Anaplasmosis Cases in Alsace
- Status
- Recruiting
- People taking part
- 100 people, planned
- Started
- 2 Oct 2024
- Planned end
- Feb 2026
- Type of study
- Observational
- Record updated
- 31 December 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults who had human anaplasmosis, a tick-borne bacterial infection, in Alsace. It looks back at past cases.
- Age
- 18 years and older
- Sex
- All sexes
- Disease stage
- Infection with Anaplasma confirmed by a PCR test
- Biomarker or test result
- A PCR test (a lab test that finds the germ's genetic material) confirming Anaplasma infection
Main reasons for not taking part
- People who refuse to take part in the study cannot join
The registry criteria, word for word
Show all 3 criteriaShow less
Who can take part
- Adult subjct (≥18 years)
- Presenting with a PCR-confirmed infection of Anaplasma
Who cannot take part
- Refusal to participate in the study
This trial is currently available in France.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Anaplasmosis is a bacterial infection caused by the intracellular bacterium Anaplasma phagocytophilum and transmitted by ticks. This bacterium is present in approximately 1% of ticks in Alsace. This infection is responsible for clinical manifestations that are most often mild, including fever, headache, and myalgia, occurring 2 to 3 weeks after a tick bite. However, this infection can be accompanied by potentially serious or even fatal complications, including severe cytopenias, acute respiratory distress syndrome, septic shock, severe neurological disorders, hemorrhagic manifestations, macrophage activation syndrome, and multiple organ failure. Mortality is variable and appears to be higher in American studies, where it is around 4%. Treatment is well-established and relies on doxycycline, which is highly effective. Although a few cases have been described in France, these are mostly isolated cases or short series of cases, whereas Belgium, Poland, and Slovenia have reported numerous cases. Thus, there is a lack of data on French cases, and given that Alsace is in a region with a high prevalence of tick-borne diseases, data is needed to better understand the epidemiology and to better identify suspected cases in order to provide appropriate care.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Epidemiological, Clinical and Biological Characteristics of Human Anaplasmosis Cases in Alsace: a Retrospective and Multicenter Study
- Plain-language title
- Looking back at human anaplasmosis cases after tick bites in AlsaceGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Record updated
- 31 December 2025